Bothell, WA-based MDRNA (NASDAQ: [[ticker:MRNA]]) said today that a generic calcitonin nasal spray for osteoporosis has received FDA approval, and has been introduced to the market. The Bothell, WA-based company sold the product in March to Woodcliff Lake, NJ-based Par Pharmaceutical (NYSE: [[ticker:PRX]]), although MDRNA still stands to receive an undisclosed profit share from the product over the next five years. MDRNA has switched its strategy from developing nasal spray products to RNA interference technology.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
